MX2021011530A - Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. - Google Patents

Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.

Info

Publication number
MX2021011530A
MX2021011530A MX2021011530A MX2021011530A MX2021011530A MX 2021011530 A MX2021011530 A MX 2021011530A MX 2021011530 A MX2021011530 A MX 2021011530A MX 2021011530 A MX2021011530 A MX 2021011530A MX 2021011530 A MX2021011530 A MX 2021011530A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
antibody against
containing antibody
disclosed
Prior art date
Application number
MX2021011530A
Other languages
English (en)
Inventor
Weikang Tao
Xun Liu
Tingting Wu
Hao Li
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021011530A publication Critical patent/MX2021011530A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En la presente solicitud se describe una composición farmacéutica que contiene un anticuerpo contra IL-5 y su uso. En particular, en la presente solicitud se describe una composición farmacéutica que contiene un anticuerpo IL-5 o un fragmento de unión a antígeno del mismo en una solución tampón. Además, la composición farmacéutica contiene un sacárido y un tensioactivo no iónico.
MX2021011530A 2019-03-29 2020-03-27 Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. MX2021011530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910249953 2019-03-29
PCT/CN2020/081701 WO2020200099A1 (zh) 2019-03-29 2020-03-27 包含抗il-5抗体的药物组合物及其用途

Publications (1)

Publication Number Publication Date
MX2021011530A true MX2021011530A (es) 2021-10-22

Family

ID=72664562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011530A MX2021011530A (es) 2019-03-29 2020-03-27 Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.

Country Status (12)

Country Link
US (1) US20220144937A1 (es)
EP (1) EP3939611A4 (es)
JP (1) JP2022528230A (es)
KR (1) KR20210145187A (es)
CN (1) CN113507938B (es)
AU (1) AU2020251627A1 (es)
BR (1) BR112021019272A2 (es)
CA (1) CA3134401A1 (es)
MX (1) MX2021011530A (es)
TW (1) TW202102204A (es)
WO (1) WO2020200099A1 (es)
ZA (1) ZA202106721B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024500308A (ja) * 2020-12-03 2024-01-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｔｓｌｐ抗体医薬組成物及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
JP3202029B2 (ja) * 1991-02-27 2001-08-27 サントリー株式会社 インターロイキン５の微量定量
WO1995014040A1 (en) * 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
CZ297045B6 (cs) * 1994-12-23 2006-08-16 Smithkline Beecham Corporation Hlodavcí neutralizacní monoklonální protilátka, zpusob pro její produkci, kompozice s jejím obsahema pouzití, hybridom a jím produkovaná protilátka,fab fragment, komplementaritu urcující region, molekula nukleové kyseliny a její sekvence, plasmid a
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
SG193963A1 (en) 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP3083682B1 (en) 2013-12-20 2024-04-17 F. Hoffmann-La Roche AG Dual specific antibodies
KR102495432B1 (ko) 2014-09-08 2023-02-03 세파론 엘엘씨 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
BR112018003741A2 (pt) * 2015-08-24 2018-09-25 Glaxosmithkline Ip No 2 Ltd composições biofarmacêuticas
CA3048186A1 (en) 2016-12-23 2018-06-28 Cephalon, Inc. Anti-il-5 antibodies
WO2018226339A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
JP7307720B2 (ja) * 2017-09-29 2023-07-12 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用

Also Published As

Publication number Publication date
CN113507938B (zh) 2024-04-16
EP3939611A1 (en) 2022-01-19
CA3134401A1 (en) 2020-10-08
EP3939611A4 (en) 2022-12-21
CN113507938A (zh) 2021-10-15
AU2020251627A1 (en) 2021-11-11
ZA202106721B (en) 2022-05-25
JP2022528230A (ja) 2022-06-09
KR20210145187A (ko) 2021-12-01
WO2020200099A1 (zh) 2020-10-08
US20220144937A1 (en) 2022-05-12
BR112021019272A2 (pt) 2022-01-04
TW202102204A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
AU2018267843A1 (en) PD-L1 antibody pharmaceutical composition and use thereof
PH12018501419A1 (en) Pharmaceutical composition comprising bispecific antibody constructs
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
PH12019501796A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
TW200732349A (en) Anti-OX40L antibodies and methods using same
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2018222722A3 (en) COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
IL285651A (en) Anti-trem2 antibodies, preparations containing them and their uses
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2020000582A (es) Composicion farmaceutica de anticuerpos sost y usos de la misma.
IL310535A (en) Anti-GDF15 antibodies, compositions and uses thereof
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CL2023000486A1 (es) Formulación farmacéutica que comprende un bite, anticuerpo biespecífico y metionina
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
MX2021011530A (es) Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
WO2023004477A8 (en) Neutralising antibodies and uses thereof
IL288753A (en) Antibodies against epcam conditional activity, antibody fragments, their immunomodules and their uses
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
EP3802596A4 (en) ANTI-IL-22 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF
WO2019195561A3 (en) Anti-tetraspanin 33 agents and compositions and methods for making and using the same
MX2022010217A (es) Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.